NCT05415007 2025-07-15
GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer
Stanford University
Phase NA Recruiting
Clinical Trials
12 trialsNCT03089554 2025-06-06
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
University of Kentucky
Phase 2 Recruiting
NCT05904236 2025-04-08
ICVB-1042
IconOVir Bio
Phase 1 Terminated
NCT01860365 2024-02-20
Measuring Concerns of Cancer Patients Referred to Complementary Medicine Treatment Integrated Within Oncology Service
Carmel Medical Center
Phase NA Unknown
NCT02193503 2023-09-28
MVX-ONCO-1 in Patients With Solid Tumor
Maxivax SA
Phase 1 Active not recruiting
NCT03881137 2022-11-09
Improved Function and Quality of Life for Older Patients Receiving Radiotherapy, Part II
Sykehuset Innlandet HF
Phase NA Completed
NCT03154671 2022-05-20
Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer
University of Toronto
Phase NA Completed
NCT04095000 2021-08-09
FACE-TC-Sp
Children's National Research Institute
Phase NA Completed
NCT02132845 2021-02-04
Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer
Fox Chase Cancer Center
Phase NA Completed
NCT02943174 2019-05-30
MIND Programme for Cancer Patients
University of Coimbra
Phase NA Completed
NCT02587819 2016-04-14
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
Biosceptre
Phase 1 Completed
NCT00874042 2012-07-23
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed